Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
NCT ID: NCT05557695
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
350 participants
OBSERVATIONAL
2022-10-17
2027-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
NCT04008706
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611
Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia
NCT04178798
National Acalabrutinib Observational Study
NCT05437250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
a. To estimate real-world progression-free survival in patients with CLL who received acalabrutinib in the first-line.
2. Secondary Objectives:
1. To estimate real-world overall survival in patients with CLL who received acalabrutinib in the first-line.
2. To describe real-world response rate to acalabrutinib in patients with CLL who received acalabrutinib in the first-line.
3. To describe the healthcare resource utilisation in patients with CLL who received acalabrutinib in the first-line.
4. To describe post-progression treatment patterns in patients with CLL who progressed from first-line acalabrutinib.
5. To describe real-world clinical progression free survival in patients with CLL who received acalabrutinib in the first-line and progressed during acalabrutinib treatment.
6. To describe acalabrutinib treatment patterns in patients with CLL who received acalabrutinib in the first-line.
7. To describe baseline clinical and demographic characteristics in patients with CLL who received acalabrutinib in the first-line.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients with chronic lymphocytic leukaemia treated with acalabrutinib in first line
Acalabrutinib
Acalabrutinib
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Acalabrutinib
Acalabrutinib
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received their first dose of acalabrutinib between 1 April 2020 and 1 April 2021
* Patients aged ≥18 years old
* Note: patients later found to have small lymphocytic lymphoma (SLL) may also be included in the EAP.
Exclusion Criteria
18 Years
130 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UKCLL Forum
UNKNOWN
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Toby A Eyre
Role: PRINCIPAL_INVESTIGATOR
Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aylesbury, , United Kingdom
Research Site
Bath, , United Kingdom
Research Site
Birmingham, , United Kingdom
Research Site
Bournemouth, , United Kingdom
Research Site
Cardiff, , United Kingdom
Research Site
Cornwall, , United Kingdom
Research Site
Dartford, , United Kingdom
Research Site
Derby, , United Kingdom
Research Site
Doncaster, , United Kingdom
Research Site
Dorset, , United Kingdom
Research Site
Eastbourne, , United Kingdom
Research Site
Hull, , United Kingdom
Research Site
Leicester, , United Kingdom
Research Site
Lincoln, , United Kingdom
Research Site
Liverpool, , United Kingdom
Research Site
London, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Mid Yorkshire, , United Kingdom
Research Site
Middlesbrough, , United Kingdom
Research Site
Newcastle, , United Kingdom
Research Site
North Shields, , United Kingdom
Research Site
Norwich, , United Kingdom
Research Site
Nottingham, , United Kingdom
Research Site
Oxford, , United Kingdom
Research Site
Plymouth, , United Kingdom
Research Site
Southampton, , United Kingdom
Research Site
Stockton-on-Tees, , United Kingdom
Research Site
Stoke-on-Trent, , United Kingdom
Research Site
Wigan, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D8220R00033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.